In animal models of obese melanoma-bearing mice, anti-PD-1 immunotherapy enhances response to cancer by increasing number and function of tumor-associated CD8+ T cells, alongside a decrease in PD-1 expression by T cells, implying that the blockade of PD-1 is able to overcome obesity-driven T-cell exhaustion [377]. The gene discussed is CD8A; the disease is neoplasm.